Suscribirse

Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia - 25/08/11

Doi : 10.1016/j.amjmed.2003.10.027 
Naoki Kotani, MD, PhD a, b, , Ryoko Kudo c, Yutaka Sakurai, MD, PhD d, Daisuke Sawamura, MD, PhD e, Daniel I Sessler, MD a, f, Hiroshi Okada, MD, PhD g, Hiroto Nakayama, MD, PhD g, Toshifumi Yamagata h, Minoru Yasujima, MD, PhD c, Akitomo Matsuki, MD, PhD c
a Outcomes Research Group (NK, DIS), Yamagata, Japan 
b Department of Anesthesiology (NK), Yamagata University, Yamagata, Japan 
c Departments of Anesthesiology and Laboratory Medicine (RK, MY, AM), University of Hirosaki, Hirosaki, Japan 
d Department of Hygiene (YS), National Defense Medical College, Tokorozawa, Japan 
e Department of Dermatology (DS), Hokkaido University, Sapporo, Japan 
f Department of Anesthesiology (DIS), University of Louisville, Louisville, Kentucky, USA 
g Department of Anesthesiology (HO, HN), Iwate Medical University, Morioka, Japan 
h Tohoku Chemical Co. Ltd (TY), Hirosaki, Japan 

*Requests for reprints should be addressed to Naoki Kotani, MD, PhD, Department of Anesthesiology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

Abstract

Purpose

Other than age, the risk factors for postherpetic neuralgia are not well established. We studied whether the concentration of interleukin 8 in the cerebrospinal fluid is associated with the risk of postherpetic neuralgia.

Methods

We enrolled 170 patients more than 50 years old who had a typical painful and nontrigeminal herpetic rash. Patients were treated with acyclovir; no corticosteroids were given. Cerebrospinal fluid was taken for analysis of interleukin 8 during and at full crusting of the herpetic rash. Age, sex, comorbid conditions, prodromal pain, localization and severity of herpetic rash, number of skin lesions, and degree of pain were recorded. We used multivariate logistic regression modeling to identify significant predictive factors. Receiver operating characteristic (ROC) curves were evaluated to determine the contribution of each factor.

Results

Six months after healing, 31 patients (18%) had postherpetic neuralgia; 27 patients still had it after 1 year. Only three variables—age (odds ratio [OR] = 2.7 per 10-year increase; 95% confidence interval [CI]: 1.2 to 6.2), acute pain (OR = 1.8 per unit increase in visual analog scale; 95% CI: 1.2 to 2.8), and interleukin 8 concentration in the cerebrospinal fluid at full crusting of the herpetic rash (OR = 1.6 per 20-μg/L increase; 95% CI: 1.3 to 2.0)—were significant predictors of postherpetic neuralgia at 1 year. Interleukin 8 concentration also had the highest area under the ROC curve at these evaluation points (P <0.001).

Conclusion

Our results suggest that interleukin 8 concentration in the cerebrospinal fluid at full crusting of herpetic rash may be useful for identifying patients who are likely to develop intractable postherpetic neuralgia.

El texto completo de este artículo está disponible en PDF.

Esquema


 This work was supported by Grants-in-aid for Scientific Research B2-30205415 and C2-14571415 from the Ministry of Education and Science, Tokyo, Japan; Grant-in-aid for Cancer Research No. 11-1 from the Ministry of Health, Labor, and Welfare, Tokyo, Japan; grants GM58273 and GM061655 from the National Institutes of Health, Bethesda, Maryland; the Joseph Drown Foundation, Los Angeles, California; and the Commonwealth of Kentucky Research Challenge Trust Fund, Louisville, Kentucky.


© 2004  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 116 - N° 5

P. 318-324 - mars 2004 Regresar al número
Artículo precedente Artículo precedente
  • Regional cerebral hypoperfusion in patients with celiac disease
  • Giovanni Addolorato, Daniela Di Giuda, Giuseppe De Rossi, Venanzio Valenza, Marco Domenicali, Fabio Caputo, Antonio Gasbarrini, Esmeralda Capristo, Giovanni Gasbarrini
| Artículo siguiente Artículo siguiente
  • Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity
  • Donald D Sin, Kamran Golmohammadi, Philip Jacobs

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.